INM 901
Alternative Names: INM-901Latest Information Update: 30 Oct 2024
Price :
$50 *
At a glance
- Originator InMed Pharmaceuticals
- Class Antidementias; Cannabinoids; Neuroprotectants; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 28 Oct 2024 InMed Pharmaceuticals files patent application under PCT for INM 901 for Alzheimer's disease
- 30 Jul 2024 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by InMed Pharmaceuticals
- 04 Apr 2024 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by InMed Pharmaceuticals